Assessing the Solubility of Baricitinib and Drug Uptake in Different Tissues Using Absorption and Fluorescence Spectroscopies

Author:

Mohammadi-Meyabadi RoyaORCID,Beirampour NegarORCID,Garrós NúriaORCID,Alvarado Helen Lissette,Limón DavidORCID,Silva-Abreu MarcelleORCID,Calpena Ana CristinaORCID,Mallandrich MireiaORCID

Abstract

The low water solubility of baricitinib (BCT) limits the development of new formulations for the topical delivery of the drug. The aims of this study were to assess the solubility of BCT in different solvents, including Transcutol, a biocompatible permeation enhancer that is miscible in water, to evaluate the drug uptake in human skin and porcine tissues (sclera, cornea, oral, sublingual, and vaginal), and to subsequently extract the drug from the tissues so as to determine the drug recovery using in vitro techniques. Analytical methods were developed and validated for the quantification of BCT in Transcutol using absorption and fluorescence spectroscopies, which are complementary to each other and permit the detection of the drug across a broad range of concentrations. Results show that Transcutol permits an increased drug solubility, and that BCT is able to penetrate the tissues studied. The solutions of BCT in Transcutol were stable for at least one week. Hence, Transcutol may be a suitable solvent for further development of topical formulations.

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference66 articles.

1. Approaches for Breaking the Barriers of Drug Permeation through Transdermal Drug Delivery;Alexander;J. Control. Release,2012

2. Transmucosal Drug Administration as an Alternative Route in Palliative and End-of-Life Care during the COVID-19 Pandemic;Lam;Adv. Drug. Deliv. Rev.,2020

3. (2022, August 09). Drug Bank Baricitinib: Uses, Interactions, Mechanism of Action. Available online: https://go.drugbank.com/drugs/DB11817.

4. National Center for Biotechnology Information (2022, January 12). PubChem Database. PubChem Compound Summary for CID 44205240, Baricitinib, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Baricitinib.

5. Emerging Systemic JAK Inhibitors in the Treatment of Atopic Dermatitis: A Review of Abrocitinib, Baricitinib, and Upadacitinib;Nezamololama;Drugs Context,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3